![](https://stabiopharma.com/wpstabio/wp-content/uploads/2021/07/p-nerlynx-kate_2.jpg)
47-year-old mother-of-two Kate Harper was diagnosed with HER2+ breast cancer in 2017. Following chemotherapy and trastuzumab-based therapy, she has commenced NERLYNX therapy. She has continued working throughout her treatment. Click on the image banner above to play the video.